Currently Fred Hirsch, MD, PhD, is adjoint professor of medicine in the Division of Medical Oncology at the University of Colorado Denver as well as the Executive Director of the Clinical Institute for Lung Cancer at Mount Sinai Health Systems. Dr. Hirsch is a professor of medicine at the Icahn School of Medicine and holds the Richard Stein, Joe Lowe and Louis Pricie endowed chair in medicine. Dr. Hirsch has worked with clinical/ translational research in lung cancer for more than 25 years. His current interest is in biomarker developments for early detection, chemoprevention and treatment of lung cancer. He is also focuses on markers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment.
The biomarker studies relate to the development of molecular targeted therapies for chemoprevention and treatment of lung cancer including studies on lung cancer cell lines and tumor tissue from clinical cohorts. Within the last years focus has been on identifying biomarkers, which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch's laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe both in lung and head and neck cancer.
Fred Hirsch, MD, PhD